Press Releases

June 18, 2018
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting Read More
June 6, 2018
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference Read More
June 1, 2018
Protagonist Therapeutics Reports Granting of Inducement Award Read More
May 24, 2018
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer Read More
May 17, 2018
Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association Read More
May 16, 2018
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors Read More
March 26, 2018
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis Read More
March 9, 2018
Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference Read More
March 7, 2018
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Read More
March 6, 2018
FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia Read More
March 1, 2018
Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference Read More
March 1, 2018
Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow Read More
January 31, 2018
Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference Read More
January 4, 2018
Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 Read More
December 14, 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors Read More
December 14, 2017
Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Read More
December 4, 2017
Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference Read More
November 9, 2017
Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 Read More
November 6, 2017
Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update Read More
November 1, 2017
Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference Read More